Recent studies provide support for the usefulness of the oral potentiator ivacaftor in patients with cystic fibrosis who are heterozygous for the G551D mutation.
1 The possibility of an increased response in persons who are homozygous for the mutation is unknown because of its low prevalence. Ivacaftor potentiates the open-channel probability of the G551D–cystic fibrosis transmembrane conductance regulator (CFTR) protein.
1 The most common cystic fibrosis mutation, F508del, results in little or no CFTR reaching the cell surface, whereas with the G551D-CFTR mutation, there are potentially normal levels of nonfunctional CFTR channels at the cell surface.
2 Therefore, we postulate the increased efficacy of ivacaftor in G551D homozygotes as compared with compound heterozygotes with a single G551D mutation. Furthermore, little is known about the response to ivacaftor in persons with a forced expiratory volume in 1 second (FEV
1) of less than 30% of the predicted value, because these persons were excluded from initial studies.
1,3